RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

–      RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults–      Also known as temporal arteritis, GCA is the most common vasculitis affecting adults in Western countries2 –      This marks the ninth approved indication for RINVOQ in the U.S., across rheumatology, gastroenterology, and dermatology1NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has app ...